Literature DB >> 22890034

Inhibitory effects of pepstatin A and mefloquine on the growth of Babesia parasites.

Tserendorj Munkhjargal1, Mahmoud AbouLaila, Mohamad Alaa Terkawi, Thillaiampalam Sivakumar, Madoka Ichikawa, Batdorj Davaasuren, Tserendorj Nyamjargal, Naoaki Yokoyama, Ikuo Igarashi.   

Abstract

We evaluated the inhibitory effects of pepstatin A and mefloquine on the in vitro and in vivo growths of Babesia parasites. The in vitro growth of Babesia bovis, B. bigemina, B. caballi, and B. equi was significantly inhibited (P < 0.05) by micromolar concentrations of pepstatin A (50% inhibitory concentrations = 38.5, 36.5, 17.6, and 18.1 μM, respectively) and mefloquine (50% inhibitory concentrations = 59.7, 56.7, 20.7, and 4 μM, respectively). Furthermore, both reagents either alone at a concentration of 5 mg/kg or in combinations (2.5/2.5 and 5/5 mg/kg) for 10 days significantly inhibited the in vivo growth of B. microti in mice. Mefloquine treatment was highly effective and the combination treatments were less effective than other treatments. Therefore, mefloquine may antagonize the actions of pepstatin A against babesiosis and aspartic proteases may play an important role in the asexual growth cycle of Babesia parasites.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22890034      PMCID: PMC3516319          DOI: 10.4269/ajtmh.2012.12-0218

Source DB:  PubMed          Journal:  Am J Trop Med Hyg        ISSN: 0002-9637            Impact factor:   2.345


  39 in total

1.  Babesia bigemina: in vitro and in vivo effects of curdlan sulfate on growth of parasites.

Authors:  I Igarashi; F K Njonge; Y Kaneko; Y Nakamura
Journal:  Exp Parasitol       Date:  1998-11       Impact factor: 2.011

2.  Purification and characterization of a hemoglobin degrading aspartic protease from the malarial parasite Plasmodium vivax.

Authors:  Arun Sharma; Alex Eapen; Sarala K Subbarao
Journal:  J Biochem       Date:  2005-07       Impact factor: 3.387

Review 3.  Human babesiosis: an emerging tick-borne disease.

Authors:  A M Kjemtrup; P A Conrad
Journal:  Int J Parasitol       Date:  2000-11       Impact factor: 3.981

4.  Structure and inhibition of plasmepsin II, a hemoglobin-degrading enzyme from Plasmodium falciparum.

Authors:  A M Silva; A Y Lee; S V Gulnik; P Maier; J Collins; T N Bhat; P J Collins; R E Cachau; K E Luker; I Y Gluzman; S E Francis; A Oksman; D E Goldberg; J W Erickson
Journal:  Proc Natl Acad Sci U S A       Date:  1996-09-17       Impact factor: 11.205

5.  Mefloquine resistance in Plasmodium falciparum.

Authors:  F P Mockenhaupt
Journal:  Parasitol Today       Date:  1995-07

6.  Effects of protein kinase inhibitors on the in vitro growth of Babesia bovis.

Authors:  S Bork; S Das; K Okubo; N Yokoyama; I Igarashi
Journal:  Parasitology       Date:  2006-02-24       Impact factor: 3.234

7.  Optimization of the suspension culture method for in vitro cultivation of Babesia bovis.

Authors:  E E Erp; R D Smith; M Ristic; B M Osorno
Journal:  Am J Vet Res       Date:  1980-12       Impact factor: 1.156

8.  Hemoglobin degradation in the human malaria pathogen Plasmodium falciparum: a catabolic pathway initiated by a specific aspartic protease.

Authors:  D E Goldberg; A F Slater; R Beavis; B Chait; A Cerami; G B Henderson
Journal:  J Exp Med       Date:  1991-04-01       Impact factor: 14.307

9.  Epileptogenic potential of mefloquine chemoprophylaxis: a pathogenic hypothesis.

Authors:  Remington L Nevin
Journal:  Malar J       Date:  2009-08-05       Impact factor: 2.979

10.  Failure of artesunate-mefloquine combination therapy for uncomplicated Plasmodium falciparum malaria in southern Cambodia.

Authors:  William O Rogers; Rithy Sem; Thong Tero; Pheaktra Chim; Pharath Lim; Sinuon Muth; Duong Socheat; Frédéric Ariey; Chansuda Wongsrichanalai
Journal:  Malar J       Date:  2009-01-12       Impact factor: 2.979

View more
  6 in total

1.  Synergistic drug combination effectively blocks Ebola virus infection.

Authors:  Wei Sun; Shihua He; Carles Martínez-Romero; Jennifer Kouznetsova; Gregory Tawa; Miao Xu; Paul Shinn; Ethan Fisher; Yan Long; Omid Motabar; Shu Yang; Philip E Sanderson; Peter R Williamson; Adolfo García-Sastre; Xiangguo Qiu; Wei Zheng
Journal:  Antiviral Res       Date:  2016-11-24       Impact factor: 5.970

2.  Bumped kinase inhibitor prohibits egression in Babesia bovis.

Authors:  Monica J Pedroni; Rama Subba Rao Vidadala; Ryan Choi; Katelyn R Keyloun; Molly C Reid; Ryan C Murphy; Lynn K Barrett; Wesley C Van Voorhis; Dustin J Maly; Kayode K Ojo; Audrey O T Lau
Journal:  Vet Parasitol       Date:  2015-11-05       Impact factor: 2.738

3.  Alsinol, an arylamino alcohol derivative active against Plasmodium, Babesia, Trypanosoma, and Leishmania: past and new outcomes.

Authors:  Maria H Arias; Miguel Quiliano; Sandra Bourgeade-Delmas; Isabelle Fabing; Isabelle Chantal; David Berthier; Cécile Minet; Veronique Eparvier; Jonathan Sorres; Didier Stien; Silvia Galiano; Ignacio Aldana; Alexis Valentin; Giovanny Garavito; Eric Deharo
Journal:  Parasitol Res       Date:  2020-08-08       Impact factor: 2.289

4.  Theileria equi isolates vary in susceptibility to imidocarb dipropionate but demonstrate uniform in vitro susceptibility to a bumped kinase inhibitor.

Authors:  Siddra A Hines; Joshua D Ramsay; Lowell S Kappmeyer; Audrey Ot Lau; Kayode K Ojo; Wesley C Van Voorhis; Donald P Knowles; Robert H Mealey
Journal:  Parasit Vectors       Date:  2015-01-20       Impact factor: 3.876

5.  Evaluation of possible prophylactic and therapeutic effect of mefloquine on experimental cryptosporidiosis in immunocompromised mice.

Authors:  Eman S El-Wakil; Amal E Salem; Asmaa M F Al-Ghandour
Journal:  J Parasit Dis       Date:  2020-11-13

Review 6.  Treatment of Human Babesiosis: Then and Now.

Authors:  Isaline Renard; Choukri Ben Mamoun
Journal:  Pathogens       Date:  2021-09-01
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.